1. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Issue 10290 (5th June 2021) Authors: Guttman-Yassky, Emma; Teixeira, Henrique D; Simpson, Eric L; Papp, Kim A; Pangan, Aileen L; Blauvelt, Andrew; Thaçi, Diamant; Chu, Chia-Yu; Hong, H Chih-ho; Katoh, Norito; Paller, Amy S; Calimlim, Brian; Gu, Yihua; Hu, Xiaofei; Liu, Meng; Yang, Yang; Liu, John; Tenorio, Allan R; Chu, Alvina D; Ir... Journal: Lancet Issue: Volume 397:Issue 10290(2021) Page Start: 2151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10290 (5th June 2021) Authors: Reich, Kristian; Teixeira, Henrique D; de Bruin-Weller, Marjolein; Bieber, Thomas; Soong, Weily; Kabashima, Kenji; Werfel, Thomas; Zeng, Jiewei; Huang, Xiaohong; Hu, Xiaofei; Hendrickson, Barbara A; Ladizinski, Barry; Chu, Alvina D; Silverberg, Jonathan I Journal: Lancet Issue: Volume 397:Issue 10290(2021) Page Start: 2169 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗